Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Catastrophic Claims Often Require Nuanced Solutions
In workers’ compensation, catastrophic injuries transpire with relatively low frequency. When they do occur, however, payers demand an all-hands-on-deck approach that calls upon specialized experts to manage specific aspects of these complicated claims.
Mitchell Diagnostics Platform Surpasses 3 Million Scans
Latest milestone achieved in less than a year due to rapid adoption and utilization of the patented collision repair diagnostic system
Mitchell Named Official Technology Provider of the Vale Paintless Dent Repair (PDR) Technician Certification Program
Designation makes Mitchell the exclusive supplier of diagnostic and calibration tools for certified PDR technicians.
FDA Approves Combination NSAID/Opioid Seglentis
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
FDA Approves Combination NSAID/Opioid Seglentis
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Specialty Services Are a Big Deal
When adjusters have to jump through hoops to make referrals, they lose precious time. When it comes to specialty services, we have your back.